
Isis Pharmaceuticals and AstraZeneca have announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal …
Biogen has signed a new deal with drug discovery firm Isis for its spinal muscular atrophy drug ISIS-SMNRx. Biogen will pay …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

